Compare DexCom, Inc. (DXCM) vs Equitable Holdings Inc. Common Stock (EQH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Equitable Holdings Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B). The key difference: DexCom, Inc. is far larger — about 2.2× Equitable Holdings Inc. Common Stock's market cap, and Equitable Holdings Inc. Common Stock pays a 2.15% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Equitable Holdings Inc. Common Stock for 0 Days on average.
| DXCM | EQH | |
|---|---|---|
Market Cap | $32.09B | $14.49B |
Volume | 3,819,730 | 2,405,401 |
Sector | Health | Financials |
52-Week High | $92.34 | $54.50 |
52-Week Low | $54.84 | $35.34 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $5.54B |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →
